Amy L. Cummings, MD, PhD

Amy L. Cummings, MD, PhD

Assistant Professor of Medicine, Department of Medicine, Hematology/Oncology





David Geffen School of Medicine at UCLA, Los Angeles, CA, 2021


PhD, David Geffen School of Medicine at UCLA, Los Angeles, CA, 2022
MD, Keck School of Medicine at the University of Southern California, Los Angeles, CA, 2013
University of California, Los Angeles, Los Angeles, CA, 2004


David Geffen School of Medicine at UCLA, Los Angeles, CA, 2016

Board Certifications

Hematology, American Board of Internal Medicine, 2021
Medical Oncology, American Board of Internal Medicine, 2020
Internal Medicine, American Board of Internal Medicine, 2016

Contact Information

Scientific Interests

Dr. Cummings' research focuses on translational biomarker applications in thoracic oncology, specifically in early-stage lung cancer clinical trials. As part of her PhD in bioengineering, she developed methodologies and benchmarking strategies for genomic similarity and outcomes comparisons as well as approaches to vertical integration, visualization, and normalization of all types of clinical data. Through her work with the Lung Correlative Team, she strives to better identify patients that will have long-term benefits to treatment as well as identify novel approaches to treatment, focusing in particular on predicition of human leukocyte antigen and neoantigen interactions.

Highlighted Publications

Cummings AL, Gukasyan J, Lu HY, Grogan T, Sunga G, Fares CM, Hornstein N, Zaretsky J, Carroll J, Bacharach B, Akingbemi WO, Li D, Noor Z, Lisberg A, Goldman JW, Elashoff D, Bui AAT, Ribas A, Dubinett SM, Rossetti M, Garon EB. Mutational landscape influences immunotherapy outcomes among non-small cell lung cancer patients with human leukoctye antigen supertype B44. (In press Nature Cancer).

Lisberg A, Cummings AL, Goldman JW, Bornazyan K, Reese N, Wang T, Coluzzi P, Ledesma B, Mendenhall M, Jones B, Madrigal J, Carroll J, Gukasyan J, Williams T, Sauer L, Wells C, Hardy A, Linares P, Adame C, Garon EB. A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC. J Thorac Oncol. 2018 Aug;13(8):1138-1145. PMID:29874546.

Fares CM, Williamson TJ, Theisen MK, Cummings AL, Bornazyan K, Carroll J, Spiegel ML, Stanton AL, Garon EB. Limited correlation seen between patient reported outcomes and either clinical or clinical trial documentation. JCO Clin Cancer Inform. 2018 Dec;2:1-12. PMID:30652613.

Noor Z, Cummings AL, Johnson MA, Spiegel M, Goldman JW. Targeted therapy for non-small cell lung cancer. Semin Respir Crit Care Med 2020 Jun;41(3):409-434. PMID: 32450595.

Cummings AL, Garon EB. The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role? Cancer Biol Med. 2017 Nov;14(4):341-347. PMID: 29372100.